Muzastotug (Not yet branded)
Other Medications
Description
Muzastotug is an experimental compound being evaluated in early-phase clinical trials for microsatellite stable (MSS) colorectal cancer. Based on the available trial data, it is being tested in combination with established therapies including leucovorin, fluorouracil, and FOLFIRI regimens, suggesting it may serve as an adjunct to standard chemotherapy protocols. The drug appears to be specifically targeted toward MSS tumors, which typically have limited response to immunotherapy approaches.
Mechanism of Action
The specific molecular mechanism of action for Muzastotug has not been fully disclosed in publicly available trial information. Given its use in combination with chemotherapy regimens and focus on MSS colorectal cancers, it likely targets pathways involved in tumor growth or immune response modulation specific to microsatellite stable disease.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
| Administration | IV |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.